SomaLogic, Inc. operates as a provider of proteomic technology platforms and related data analysis services for biological research. The company delivers high-throughput, multiplex proteomics solutions, including the SomaScan assay for measuring thousands of proteins from various sample types. It offers fee-for-service proteomic analysis at CLIA-certified, CAP-accredited laboratories and through a global network of authorized sites, as well as data consulting services that include bioinformatics support for study design, quality control, data analysis, and biomarker discovery. The company provides software tools such as the SomaDataIO package for proteomic data management and access to additional research tools and platforms, including genomic workstations and technologies such as Krex, CyTOF, and Hyperion. Its solutions support research in neurological diseases, type 2 diabetes, non-alcoholic steatohepatitis, rare diseases, and drug discovery. The company serves research organizations and professionals involved in basic, preclinical, and clinical research, as well as laboratories and institutions conducting studies in various therapeutic areas. The company was founded in 2000 and is based in Boulder, Colorado. As of January 30, 2026, SomaLogic, Inc. operates as a subsidiary of Illumina, Inc.